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Abstract
Objective: To examine any possible links between
exposure to DDE (1,1›dichloro›2,2›bis
(p›chlorophenyl)ethylene), the persistent metabolite of
the pesticide dicophane (DDT), and breast cancer.
Design: Multicentre study of exposure to DDE by
measurement of adipose tissue aspirated from the
buttocks. Laboratory measurements were conducted
in a single laboratory. Additional data on risk factors
for breast cancer were obtained by standard
questionnaires.
Setting: Centres in Germany, the Netherlands,
Northern Ireland, Switzerland, and Spain.
Subjects: 265 postmenopausal women with breast
cancer and 341 controls matched for age and centre.
Main outcome measure: Adipose DDE
concentrations.
Results: Women with breast cancer had adipose DDE
concentrations 9.2% lower than control women. No
increased risk of breast cancer was found at higher
concentrations. The odds ratio of breast cancer,
adjusted for age and centre, for the highest versus the
lowest fourth of DDE distribution was 0.73 (95%
confidence interval 0.44 to 1.21) and decreased to
0.48 (0.25 to 0.95; P for trend = 0.02) after adjustment
for body mass index, age at first birth, and current
alcohol drinking. Adjustment for other risk factors did
not materially affect these estimates.
Conclusions: The lower DDE concentrations
observed among the women with breast cancer may
be secondary to disease inception. This study does not
support the hypothesis that DDE increases risk of
breast cancer in postmenopausal women in Europe.
Introduction
Environmental oestrogenic compounds, such as the
organochlorines DDT (dicophane (2,2›bis(p›chloro›
phenyl)›1,1,1›trichloroethane)), polychlorinated bi›
phenyls, and dioxins, have been linked to altered sexual
development in various species, to a decrease in semen
quality, and to an increased risk of breast cancer in
women.1›3 Their weak oestrogenic effects may result
from altered metabolism and competition for binding to
cytosolic and nuclear receptors of steroid hormones.4 5
Because of their lipophilicity and long half lives,
organochlorines accumulate in the food chain.6
Typically, consumption of fish, meat, and milk is held
responsible for the age related increase in concentra›
tions of DDT and its even more persistent metabolite
DDE (1,1›dichloro›2,2›bis(p›chlorophenyl)ethylene) in
adipose tissue.7 Since the ban on DDT in Western
countries 20›25 years ago, DDE concentrations in
adipose tissue and mothers’ milk dropped in successive
cohorts but less so in the generations exposed before
the ban.6 8 9
Apart from some early reports,10›12 one nested case›
control study in the United States showed a fourfold
increased risk of breast cancer at high plasma DDE
concentrations,13 which was not confirmed by a larger
prospective study, also from the United States.14 We
determined the association between DDE and breast
cancer among 606 women from five European
countries on the basis of DDE measured in adipose tis›
sue aspirated from the buttocks.
Subjects and methods
This investigation is an extension of the European
study on antioxidants, myocardial infarction, and
cancer of the breast (EURAMIC). This multicentre
case›control study included 347 women with breast
cancer from Germany, the Netherlands, Northern
Ireland, Switzerland, and Spain as well as 374 popula›
tion and hospital controls.15 16 In short, apparently
healthy postmenopausal women, aged 50 to 74 years,
with a stable dietary pattern and no history of breast
cancer were eligible. To achieve efficiency in study con›
duct and data analysis we aimed at a similar number of
cases and controls by study centre and age using group
matching. Incident cases with histologically confirmed
ductal breast cancer, primary tumour < 5 cm, axillary
lymph nodes stage < N3, and no clinical indication of
distant metastases at discharge were included.
Response rates among women with cancer were
75% (Germany), 76% (Northern Ireland), 92%
(Switzerland), and 97% (Netherlands, Spain). Controls
were obtained from the hospital catchment area by
using registries of local municipalities (Switzerland and
Germany with response rates of 22% and 45%) and
general practitioners as the sampling frame (Northern
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Ireland, Netherlands, and Spain with response rates of
46%, 50%, and 91%). Information on factors relevant
to breast cancer was obtained by similarly formatted
centre specific questionnaires, with a priori specified
variables for central data analysis. Procedures for sam›
pling and data collection were approved by local ethics
committees in each participant’s country. Informed
consent was obtained from eligible subjects.
Needle aspirates were taken from the subcutaneous
fat of the buttocks in 317 women with cancer and 367
controls.15›17 For the cancer patients the fat aspirates
were taken within seven days after hospital admission.
After the exclusion of five subjects for whom relevant
background data were missing, fat aspirates of 265
cases and 341 controls were available for laboratory
analysis—that is, DDE was analysed in 84% and 93% of
the aspirates obtained. This percentage is lower in the
cases because for one of the centres the aspirates had
to be collected in several hospitals by different staff, less
skilled in fat aspiration. To facilitate the standardising
and instructing of the skills for fat aspiration, a
videotape was prepared and distributed among all
centres before the start of the project. In the four other
centres this apparently led to good results as sufficient
amounts of fat could be aspirated from 91% of the
cases and 93% of the controls in these centres. After
local storage at − 70˚C and shipment on dry ice,
samples were analysed centrally for vitamins and fatty
acids.15 16
Laboratory analyses of DDE were conducted at the
National Institute of Public Health and Environmental
Protection (Bilthoven, Netherlands), with sample vials
randomised before laboratory analyses and staff
blinded to disease status. The initial iso›octane extracts
contained the methylated fatty acids and hepta›
decanoic acid (C17:0) as an internal standard. This
solution was subjected to hyphenated chromato›
graphy, in which liquid chromatography was coupled
on line to capillary chromatography. This analysis was
carried out on a commercially available liquid
chromatography›gas chromatography system (Dual›
chrom 2000; Carlo Erba Instrument, Milan, Italy)
equipped with a Ni63 electron capture detector. The
liquid chromatography injection volume was 50 ìl.
The on column interface was used to transfer a volume
of 200 ìl into the column. The chromatographic
columns were a liquid chromatography column of
50 mm × 1 mm internal diameter packed with 3 ìm
hypersil silica and a DB5MS gas chromatography
column (30 m × 0.32 mm internal diameter, film thick›
ness 0.5 ìm). The C17:0 content was determined by
gas chromatographic analysis. When the concentration
of DDE was below the detection limit (n = 19) half the
lowest concentration in the remaining samples was
entered. The coefficient of variation within each batch
varied from 1% to 5% for C17:0 and from 1% to 8% for
DDE and between batches from 7% to 8% for C17:0
and from 8% to 11% for DDE. Concentrations of DDE
are expressed in micrograms of DDE per gram of fatty
acids in the aspirate.
Data analyses were performed with sas statistical
software.18 Although skewed distributions of DDE
required log transformations in data analysis, results
presented are geometric means. Crude means as well
as means adjusted for age and centre were calculated
for DDE and major risk factors for breast cancer. To
identify potential confounders, mean levels of risk
factors for breast cancer were compared among
fourths of DDE concentration in controls. Odds ratios
(and 95% confidence intervals) for breast cancer were
obtained from multivariate logistic regression analysis
by modelling DDE, firstly in fourths and then as a con›
tinuous variable, and contrasting the risk for subjects
on the 75th and 25th centiles. In tests for trend, the
median DDE concentration in each fourth was used.
Interaction terms between DDE and body mass index,
waist : hip ratio, fat mass, parity, hormone replacement
therapy, oestrogen receptor status, time since meno›
pause, previous benign breast disease, family history of
breast cancer, and current alcohol use were tested, but
none was significant.
Results
Table 1 shows risk factors among cases and controls.
Age was similar because of the matched design.
Women with breast cancer had significantly higher
body mass indices, waist : hip ratio, age at first birth, and
family history of breast cancer. No other significant
differences were found.
Among controls, body mass index (kg/m2) was
positively associated with DDE concentration and
increased from 24.9 (SD 4.0) in the lowest fourth to
28.2 (4.7) in the highest fourth (P < 0.01). Waist : hip
ratio increased from 0.83 (0.08) to 0.86 (0.06)
(P = 0.03). Reported history of benign breast disease
differed between fourths of DDE (P = 0.05), ranging
from 13.1% (10.2%) in the second to 3.6% (10.8%) in
the fourth. Current alcohol use was more prevalent in
the lowest than in the highest fourth (57.4 (7.9%) v 40.2
(8.5%); P < 0.01).
Mean DDE concentration was 1.35 ìg/g and
1.51 ìg/g among cases and controls, respectively, a
difference of − 10.5%, which changed little after adjust›
ment for age and centre ( − 9.2%; P = 0.36; table 2).
Concentrations were lower among cases than among
controls in all but one centre (the Netherlands). DDE
concentrations ranged from 2.5›fold to 3›fold between
countries, being lowest in Northern Ireland and
highest in Spain. Within controls, the median exposure
in the lowest (0.40 ìg/g) versus the highest fourth
(5.07 ìg) differed 12.5›fold (table 3). The odds ratio for
breast cancer, adjusted for age and centre, for the high›
est versus the lowest fourth of DDE was 0.73, but the
test for trend was not significant (P = 0.16). Adjustment
for body mass index, age at first birth, and current alco›
hol consumption strengthened the inverse association
(P for trend = 0.02), with the odds ratio in the highest
fourth showing a significant 52% risk reduction. The
largest change in the odds ratio occurred when body
mass index was entered into the model, which made
further adjustment for waist : hip ratio superfluous.
When DDE was modelled as a continuous variable, the
odds ratio for a subject at the 75th versus the 25th cen›
tile (3.46 v 0.86 ìg/g) was 0.84 (95% confidence inter›
val 0.73 to 0.97). Further adjustment for waist : hip
ratio, history of previous benign breast disease, family
history of breast cancer, and years since menopause
did not materially affect the risk estimates.
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Discussion
Our study did not confirm the hypothesis that DDE
concentrations in adipose tissue are higher in women
with breast cancer. In contrast, we observed an overall
inverse association between DDE and breast cancer,
which was consistent in most of the study centres.
Interpretation of results
In the EURAMIC study, we assessed DDE in fat
aspirates rather than plasma, and subjects who had lost
over 5 kg of body weight in the past year were not
eligible. These characteristics are important for dimin›
ishing random misclassification and for preventing
information bias in the case›control design. Response
rates of women with cancer ranged from 75% to 97%
compared with 22% to 45% among population
controls (Switzerland, Germany) and from 46% to 91%
when control recruitment was mediated by general
practitioners (see methods).
Case›control differences in the DDE concentra›
tions were largest in the centre that contributed the
smaller number of subjects to the dataset (table 2).
Although part of this difference may have resulted
from a less successful aspiration technique in this cen›
tre, it might be due to chance as well, and because of
the small number of subjects it will not have affected
the main findings and conclusions. Moreover, the case›
control differences in DDE concentrations specific for
centre were not obviously related to response rates or
to control selection procedures.
The overall ratio of the DDE concentration in cases
and controls was 0.89 (1.35:1.51; see table 2), and it was
slightly closer to 1.0 in the three centres that had
higher response rates because controls were obtained
by general practitioners (Spain 0.82, Northern Ireland
0.96, Netherlands 1.05) than in the centres that
obtained their controls through population registers
(ratio in Switzerland 0.89, in Germany 0.68). Although
this might suggest some bias towards an inverse associ›
ation between DDE and breast cancer, multivariate
adjustment for age at first birth, alcohol, and body mass
index will have attenuated biases resulting from subject
recruitment and risk factors for breast cancer. Finally,
the observed associations between breast cancer and
body mass index, reproductive factors, and familial risk
are consistent with those reported in the literature,
adding credibility to the internal validity of our results.
The discrepant findings from case›control studies
may be attributable to subject recruitment and choice
of biomarker. In early studies, DDE concentrations in
plasma, mammary fat, or tumours from patients with
breast cancer were compared with those in healthy
subjects and patients with other diseases.10›12 19 20
Although some of these studies reported higher
concentrations of DDE among cases, given the study
design and small number of subjects (not exceeding 44
cases and 33 controls) it is difficult to regard the
conclusions as definitive.
Comparison with other research
Table 4 summarises the main results as well as popula›
tion and design characteristics of the three largest
studies on DDE and breast cancer, including the
EURAMIC study. The negative findings from Krieger’s
prospective study arise from data which, having been
Table 2 DDE concentrations in cases and controls by study centre and overall
(EURAMIC breast cancer study 1991›2)
Centre Cases Controls
Mean DDE concentration (ìg/g) (95% CI)*†
Cases Controls
Germany 9 53 1.02 (0.33 to 3.20) 1.70 (1.32 to 2.18)
Netherlands 60 58 1.38 (0.99 to 1.91) 1.32 (0.98 to 1.79)
Northern Ireland 90 95 0.99 (0.78 to 1.26) 1.03 (0.80 to 1.33)
Switzerland 50 71 1.17 (0.80 to 5.98) 1.32 (0.95 to 1.84)
Spain 56 64 2.56 (1.83 to 3.59) 3.13 (2.31 to 4.24)
Overall crude means 265 341 1.35 (1.15 to 1.58) 1.51 (1.31 to 1.73)
* Means and 95% confidence intervals transformed from analysis on log scale.
† Difference (95% CI) adjusted for age and centre=−9.2% (−25.3 to 10.5).
Table 3 Odds ratio of breast cancer for fourths of distribution of DDE concentrations
in adipose tissue (EURAMIC breast cancer study 1991›2)
Fourth*
1 2 3 4
P for
trend
Median exposure to DDE (ìg/g) 0.40 1.41 2.50 5.07
No of cases/controls 73/85 75/85 63/85 54/86
Odds ratio adjusted for age and
centre (95% CI)
1.00 1.06
(0.68 to 1.68)
0.92
(0.57 to 1.48)
0.73
(0.44 to 1.21)
0.16
Multivariate odds ratio† (95%CI) 1.00 1.14
(0.62 to 2.12)
0.71
(0.38 to 1.34)
0.48
(0.25 to 0.95)
0.02
*Quartiles, based on distribution among controls, were 0.86, 1.89, and 3.46 ìg/g.
† Adjusted for age, centre, body mass index, age at first birth, alcohol consumption.
Table 4 Main characteristics and results of three largest studies on DDE and breast
cancer
Detail
Krieger et al
(1994)
Wolff et al
(1993)
EURAMIC
(1996)
Population characteristics*:
Mean age (years) 45† 51 62
Postmenopausal (%) 79 40 100
DDE in blood controls (ppb) 43.1 7.7 2.5‡
Design characteristics:
Study design Prospective Prospective Case›control
Case group 14 Year follow up Prevalent cases Clinical cases
Biomarker Blood serum Blood serum Adipose tissue
No of cases/controls 150/150 58/171 265/341
Main results:
Odds ratio in fourths§ (95% CI) 1.33 (0.68 to 2.62) 3.68 (1.01 to 13.50) 0.48 (0.25 to 0.95)
Continuous¶ odds ratio (95% CI) 1.0 (0.7 to 1.4) 1.7 (1.2 to 2.5) 0.84 (0.7 to 1.0)
ppb = Parts per billion.
* At time of (initial) assessment of exposure.
† Age at sample collection; average age at diagnosis was 59 years.
‡ Inferred from concentration in adipose tissue, assuming 610›fold lower concentrations in plasma.21
§ Adjusted odds ratio, highest v lowest third (Krieger et al), fifth (Wolff et al) and fourth (EURAMIC),
respectively.
¶Comparing women at 75th v 25th centile—that is, 57.3 v 25.8 ppb (Krieger et al), 10.34 v 3.76 ppb (Wolff
et al), and 3.46 v 0.86 ìg/g (EURAMIC), respectively.
Table 1 Description of study population (EURAMIC breast cancer study 1991›2).
Values are means (SD) except for proportions, which are means (SE)
Risk factor Cases (n=265) Controls (n=341) P value for difference
Age (years) 62.3 (6.0) 62.3 (5.5) 0.99
Body mass index (kg/m2) 27.1 (5.0) 26.3 (4.5) 0.04
Weight : hip ratio 0.87 (0.07) 0.85 (0.08) 0.00
Age at menarche (years) 13.7 (1.8) 13.6 (1.5) 0.75
Age at menopause (years) 48.4 (4.8) 48.5 (5.3) 0.86
Nulliparous (%) 24.3 (2.6) 22.0 (2.2) 0.50
Age at first birth (years)* 26.8 (4.9) 25.5 (4.4) 0.00
Family history (%) 27.3 (2.7) 18.0 (2.1) 0.01
Previous benign breast disease (%) 7.7 (1.6) 6.6 (1.3) 0.58
Smoking (%) 18.2 (2.4) 16.7 (2.0) 0.64
Alcohol (%) 51.3 (3.1) 56.0 (2.7) 0.30
*Among parous women.
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collected before the ban on DDT and many years
before diagnosis of breast cancer, showed high
concentrations of DDE with a wide range.14 The results
from the two case›control studies relate to exposure
levels about 10›fold lower and a range in exposure
5›fold to 6›fold narrower, clearly relating to women
who were exposed for a shorter period of their lives.13 16
The small nested case›control study by Wolff et al
(table 4) was a preliminary report which used
prevalent, subclinical cases, in which blood samples
had been taken from the patients six months or less
before diagnosis. We used adipose DDE concentrations
to obtain a long term preclinical reference period
within one week after diagnosis and excluded subjects
with clear weight loss, thereby providing a more robust
assessment of exposure. Although serum and adipose
DDE concentrations are highly correlated in healthy
women (r = 0.94),22 this may not extend to women with
disease. Metabolic changes secondary to disease
inception but preceding clinical diagnosis may
mobilise fat stores, leading to increased plasma
concentrations and even to some decrease in DDE
concentrations in adipose tissue.
To explain the discrepancy between the Wolff and
Krieger papers, it has been postulated that previously
higher concentrations of the more potent anti›
oestrogen dioxin have masked the risks of the weakly
oestrogenic DDE in the Krieger study,23 but our results
do not support this explanation. Similarly, one could
argue that the weakly oestrogenic effects of DDE might
be measurable only at low background concentrations
of endogenous oestrogens—that is, after menopause.
No evidence of weaker associations after menopause
was reported by Wolff or Krieger, and the inverse
association we observed in our study among post›
menopausal women does not support this idea either.
As lactation is a major route of excretion of DDE in
women, parity and duration of lactation have both
been associated with lower concentrations of DDE in
women.24›27 With the possible exception of prolonged
lactation, breast feeding is not considered to provide
substantial protection against breast cancer within the
populations represented in this study and had not
been included in our questionnaires. Therefore, like
Krieger et al,14 we adjusted for parity and age at first
birth as proxy variables, but the odds ratio was not
materially affected. In the case›control study by Wolff et
al, which did provide data on lactation, the positive
association between DDE and breast cancer increased
by almost 40% after adjustment.13 In our data, this
would increase the odds ratio of 0.48 (for highest
versus lowest fourth of DDE) to about 0.7, consistent
with our conclusion of lack of association.
Conclusions
When we consider the characteristics of the epi›
demiological studies on DDE and breast cancer, the
apparently conflicting results may be due to a
combination of chance and mobilisation of energy
from fat stores in the cases. Although these results do
not support complex biological interactions between
DDE and other environmental or endogenous
(anti)oestrogens, the recent observation of a 1000›fold
potentiation by combinations of two environmental
oestrogens28 (but not DDE) suggests that these
substances may be related to a wide range of health
effects. Whatever the reality, the results of this large
case›control study are clearly incompatible with a sub›
stantially increased risk of breast cancer among
European women with high DDE concentrations.
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Case›control study of oestrogen replacement therapy and
risk of cervical cancer
Fabio Parazzini, Carlo La Vecchia, Eva Negri, Silvia Franceschi, Simona Moroni, Liliane Chatenoud,
Giorgio Bolis
Abstract
Objective : To examine the relation between use of
oestrogen replacement therapy and risk of cervical
cancer.
Design : Case›control study.
Setting : Northern Italy.
Subjects : 645 women aged 40›75 years with cervical
cancer admitted between 1981 and 1993 to university
and general hospitals. The control group consisted of
749 women aged 40›75 years admitted to the same
hospitals with acute conditions judged to be unrelated
to any of the known or suspected risk factors for
cervical cancer.
Main outcome measures : Use of oestrogen
replacement therapy and risk of cervical cancer.
Results : 40 cases versus 86 controls had ever used
oestrogens, and the corresponding multivariate odds
ratio was 0.5 (95% confidence interval 0.3 to 0.8). The
odds ratios of cervical cancer decreased with duration
of use, being 0.6 (0.4 to 1.1) for less than 12 months’
use and 0.5 (0.2 to 1.0) for use for 12 months or more
compared with never users. The protection tended to
be somewhat stronger for women reporting first
oestrogen use before age 50. The odds ratio was 0.9
(0.5 to 1.7) for women who had taken oestrogens
within the past 10 years and 0.4 (0.2 to 0.7) for those
who had taken them 10 or more years ago.
Conclusion : These findings suggest that exogenous
oestrogens do not increase the risk of cervical cancer
and may decrease the risk.
Introduction
Convincing epidemiological evidence exists that
hormonal factors have a role in the development of
cervical cancer. For example, several studies have
shown that parity1›3 and use of oral contraceptives1 4 5
increase the risk of invasive cervical cancer. These find›
ings suggest that oestrogen›progestin stimulation can
favour, or accelerate, cervical carcinogenesis, possibly
through glucocorticoid dependent oncogenic trans›
formation by selected papilloma viruses.6 It has also
been suggested that this may be a hormone mediated
effect on one of the late stages of carcinogenesis.7
Little information is available, however, on the
separate role of oestrogens and progestogens on
cervical carcinogenesis. In particular, few data have
been published on the potential relation between
oestrogen replacement therapy and risk of invasive
cervical cancer.8 We present the results of a
case›control study of the effects of oestrogen
replacement therapy on cervical cancer.
Subjects and methods
The design of this study has been described.3 Briefly,
the study was a hospital based case›control investiga›
tion conducted in the greater Milan area, Northern
Italy, on 645 women aged 40›75 years with
histologically confirmed invasive cervical cancer who
were admitted during 1981›93 to the obstetrics and
gynaecology clinics of the University of Milan, the
National Cancer Institute, and the Ospedale Maggiore
of Milan (which includes the four largest hospitals in
Milan). Of these women, 368 (57%) had squamous
cancers and 116 (18%) adenocarcinoma; the 161 (25%)
remaining women had another or undefined histo›
logical type. The comparison group consisted of 749
women aged 40›75 years with acute conditions judged
to be unrelated to any of the known or suspected risk
factors for cervical cancer who were admitted to the
same hospitals where the cases had been identified
(mainly the Ospedale Maggiore and several specialised
university clinics). The control women were therefore
from similar catchment areas to the cases. Controls
were not individually matched but selected within
comparable age strata of cases. They were not included
if they were admitted for gynaecological, hormonal, or
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neoplastic diseases or had had a total hysterectomy. Of
the 749 controls, 202 (27%) were admitted for trauma
(mostly fractures and sprains), 270 (36%) had
non›traumatic orthopaedic disorders (mostly lower
back pain and disc disorders), 97 (13%) surgical
conditions (mostly abdominal, such as acute appendi›
citis or strangulated hernia), and 180 (24%) other
illnesses such as ear, nose, and throat or dental
disorders. Less than 2% of eligible women (cases and
controls) refused to be interviewed.
The structured questionnaire included information
on personal characteristics and habits; education and
other socioeconomic factors; general lifestyle habits
such as smoking and alcohol and coffee consumption;
a few indicators of sexual habits; gynaecological and
obstetric data; number of cervical smears; related
medical history; and lifetime use of oral contraceptives,
hormonal replacement therapy in menopause, and
female hormone preparations for other indications.
The time and duration of each episode of use and
brand name were registered, whenever available. Lists
of the most common female hormone preparations
(covering over 90% of those marketed over the past
two decades) were provided to assist recall.
All interviews were conducted in hospital. The
same questionnaire was used for cases and controls,
and the same interviewers interviewed cases and
controls.
Analysis of data
We calculated odds ratios of cervical cancer and the
corresponding 95% confidence intervals for various
measures of use of oestrogen replacement therapy
after adjustment for age.9 We also used unconditional
multiple logistic regression, fitted by the method of
maximum likelihood, including terms for age in quin›
quennia, calendar year at interview, social class, parity,
number of sexual partners, oral contraceptive use, life›
time number of cervical smears, smoking habits,
menopausal status, and various characteristics of
oestrogen replacement therapy use.10
Results
Table 1 gives the distribution of cases and controls
according to age and selected risk factors for cervical
cancer. Cases reported more sexual partners and
births than controls and significantly fewer cervical
smear tests.
Table 2 gives the relative risks for use of oestrogen
replacement therapies. Forty cases versus 86 controls
had ever taken oestrogens, and the corresponding
multivariate odds ratio was 0.5 (95% confidence inter›
val 0.3 to 0.8). Five cases and six controls reported
combined oestrogen and progestogen use. The odds of
cervical cancer fell with duration of use, being 0.6 (0.4
to 1.1) for use for under 12 months and 0.5 (0.2 to 1.0)
for 12 months or more compared with never users.
The protection tended to be somewhat stronger for
women reporting first oestrogen use before the age of
50. The odds ratio was 0.9 (0.5 to 1.7) for women who
had taken oestrogens within the past 10 years and 0.4
(0.2 to 0.7) for those who had taken them 10 or more
years ago.
Discussion
This is one of few epidemiological studies on a
meaningful number of subjects that provides reassur›
ing information on oestrogen use and cervical
carcinogenesis. The potential limitations of this study
should, however, be considered. Firstly, the study was
hospital based, with subjects collected from the main
general and teaching hospitals in the greater Milan
area. Although the study protocol indicated that all
new consecutive cases should be interviewed, the
design was not strictly population based, and it is likely
that some subjects did not enter the study (for instance,
because they were not present in the ward at the time
of the interviewer’s visit). Furthermore, women
admitted to general and teaching hospitals are
different from those treated in private or smaller
institutions in terms of sociodemographic character›
istics, and social class is related to use of oestrogen
replacement therapy.11
Another important concern is the inclusion in the
comparison group of subjects with orthopaedic
Table 1 Distribution of 645 cases of cervical cancer and 749 controls according to
selected characteristics, Italy 1981›93
No (%) of cases No (%) of controls Odds ratio (95% CI)*
Age (years):
<45 93 (14) 75 (10) —
45›54 204 (32) 219 (29) —
55›64 212 (33) 254 (34) —
>65 136 (21) 201 (27) —
Education (years):
<7 464 (72) 461 (62) 1†
7›11 113 (18) 188 (25) 0.8 (0.6 to 1.1)
>12 68 (11) 100 (13) 0.8 (0.5 to 1.2)
Menopausal status:
Premenopausal or menopausal 230 (36) 172 (23) 1†
Postmenopausal 415 (64) 576 (77) 0.6 (0.4 to 0.8)
Unknown 0 1 (1) —
Parity:
0 65 (10) 122 (16) 1†
1 125 (19) 190 (25) 1.1 (0.7 to 1.7)
>2 451 (70) 437 (58) 2.0 (1.3 to 3.1)
Unknown 4 (1) 0 —
No of sexual partners:
0 10 (2) 41 (5) 0.3 (0.1 to 0.7)
1 477 (74) 598 (80) 1†
2 84 (13) 68 (9) 1.8 (1.2 to 2.6)
>3 67 (10) 32 (4) 3.5 (2.1 to 3.8)
Unknown 7 (1) 10 (1) —
Oral contraceptive use:
Never 584 (91) 701 (94) 1†
Ever 61 (9) 48 (6) 1.4 (0.9 to 2.2)
Lifetime No of cervical smear tests:
0 407 (63) 257 (34) 1†
1 94 (15) 105 (14) 0.5 (0.3 to 0.7)
2 34 (5) 62 (8) 0.3 (0.2 to 0.5)
>3 105 (16) 313 (42) 0.2 (0.1 to 0.3)
Unknown 5 (1) 12 (2) —
Smoking status:
Never 454 (70) 538 (72) 1†
Ever 191 (30) 211 (28) 1.1 (0.9 to 1.5)
Social class:
Low 260 (40) 311 (42) 1†
Medium 242 (38) 291 (39) 1.2 (0.9 to 1.6)
High 32 (5) 69 (9) 0.8 (0.5 to 1.3)
Unknown 111 (17) 78 (10) —
*Multivariate estimates including the listed variables except education calendar plus year at interview.
†Reference category.
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diseases or trauma. Women with fractures or sprains
may represent a group unusually active and therefore
fitter than the cases. Alternatively, they may be
selectively oestrogen deficient. These potential biases
might, however, tend to reduce the protective effect of
oestrogen observed in this analysis. We found no
difference in the estimated odds ratio when the analy›
sis was conducted after exclusion of controls with
orthopaedic diseases or trauma (multivariate odds
ratio for ever v never users 0.6, 95% confidence interval
0.3 to 1.1). Another potential limitation of this study is
the low prevalence of menopausal replacement
treatment in the population, which hampered detailed
analysis of subgroups and interactions and might be
the cause of selective mechanisms. However, the
proportion of women taking oestrogen in the series
was consistent with national data in Italy.12
With regard to other potential sources of bias,
participation was almost complete, and there is no
reason to suggest differential recall of hormone use by
cases and controls. If anything, women with cervical
cancer would be more likely (rather than less) to recall
taking female hormones. Furthermore, the hospital
based design may improve the comparability of drug
recall by cases and controls.13 In addition, adjustment
for several potential confounding factors did not
substantially modify the odds ratios.
More accurate adjustment for confounding could
further reduce the apparent association between
oestrogens and risk of cervical cancer. However, the
inclusion of terms for education and age at
menopause, which may well imply overadjustment,
gave an odds ratio of 0.7 (0.4 to 1.0).
Association with cervical cancer
The inverse association between oestrogen replace›
ment therapy and cervical cancer may derive from the
fact that women receiving oestrogen replacement
therapy are screened more frequently than the
background population. Thus precancerous lesions
(dysplasia and carcinoma in situ) could be diagnosed
and treated. However, the inclusion of number of
smear tests in the multivariate analysis did not change
the estimated relative risks.
Determination of the role of oestrogen replace›
ment therapy in the onset of invasive cervical cancer is
important to the understanding of the actions of
oestrogens and progestogens. Human papillomavirus
16, the most important cause of cervical cancer,
contains a progesterone/glucocorticoid response ele›
ment upstream to the common E6/E7 promoter,14 and
progesterone enhances the ability of the viral DNA to
transform cells.15 In fact, papillomavirus lesions are
exacerbated during pregnancy16 and risk of cervical
cancer is increased by oral contraceptives and
pregnancy when progestogen levels are high.1 3 4 17
Oestrogen increases human papillomavirus expres›
sion by upregulation of the progesterone receptor.18
However, lack of progesterone in postmenopausal
women may explain the lack of adverse effect or even
the protection by oestrogen replacement therapy. Our
results agree with those from a Swedish cohort study of
the long term effect of oestrogen replacement therapy
on cancer in hormonal target organs which reported a
lower risk of cervical cancer in women receiving
oestrogen treatment.8
In conclusion, although our findings suggest that
exogenous oestrogens do not increase the risk of
cervical cancer, the biological interpretation is not
obvious. In general, epidemiological results for cervical
cancer show an opposite pattern to those of endo›
metrial cancer.19 This may support a favourable effect
of oestrogens (which increase the risk of endometrial
cancer19) on cervical carcinogenesis. Further studies on
the effect of oestrogen on cervical carcinogenesis are
clearly warranted.
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Retrospective study of doctors’ “end of life decisions” in
caring for mentally handicapped people in institutions in
the Netherlands
G J M W van Thiel, J J M van Delden, K de Haan, A K Huibers
Abstract
Objectives: To gain insight into the reasons behind
and the prevalence of doctors’ decisions at the end of
life that might hasten a patient’s death (“end of life
decisions”) in institutions caring for mentally
handicapped people in the Netherlands, and to
describe important aspects of the decisions making
process.
Design: Survey of random sample of doctors caring
for mentally handicapped people by means of self
completed questionnaires and structured interviews.
Subjects: 89 of the 101 selected doctors completed
the questionnaire. 67 doctors had taken an end of life
decision and were interviewed about their most recent
case.
Main outcome measures: Prevalence of end of life
decisions; types of decisions; characteristics of
patients; reasons why the decision was taken; and the
decision making process.
Results: The 89 doctors reported 222 deaths for
1995. An end of life decision was taken in 97 cases
(44%); in 75 the decision was to withdraw or withhold
treatment, and in 22 it was to relieve pain or
symptoms with opiates in dosages that may have
shortened life. In the 67 most recent cases with an
end of life decision the patients were mostly
incompetent (63) and under 65 years old (51). Only
two patients explicitly asked to die, but in 23 cases
there had been some communication with the patient.
In 60 cases the doctors discussed the decision with
nursing staff and in 46 with a colleague.
Conclusions: End of life decisions are an important
aspect of the institutionalised care of mentally
handicapped people. The proportion of such
decisions in the total number of deaths is similar to
that in other specialties. However, the discussion of
such decisions is less open in the care of mental
handicap than in other specialties. Because of
distinctive features of care in this specialty an open
debate about end of life decisions should not be
postponed.
Introduction
The life of mentally handicapped people is usually
strongly influenced by the care of others because most
of them are dependent on help with all types of
activities. Also, many of the decisions of other people
have repercussions on their way of living and dying, an
important example being decisions at the end of life
that might hasten death (“end of life decisions”). Six
years ago data from the Netherlands (published in the
so called Remmelink report) offered insight into the
end of life decisions made by doctors in hospitals,
family practice, and nursing homes but not by doctors
caring for mentally handicapped people.1 2 Recently,
the study was repeated,3 but, again, there were no spe›
cific data on mental handicap. How many people in the
Netherlands are mentally handicapped is unknown,4
but about 31 000 people live in 136 institutions.5 Until
recently, end of life decisions by doctors caring for
mentally handicapped people have been discussed
only among people directly concerned with a specific
case. One of the reasons for the lack of public debate is
that there is no insight into what is happening. We
therefore performed a nationwide retrospective study
of doctors’ end of life decisions for mentally
handicapped patients in institutionalised care, with the
aim of discovering what type of decisions had been
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taken, the prevalence of such decisions, and the impor›
tant aspects of the decision making process.
Subjects and methods
The study population consisted of doctors. Although
nurses and the patients’ representatives usually partici›
pate in decision making, the doctor has final responsi›
bility for medical decisions. There is no official registry
of doctors working in the care of mentally handi›
capped people but most are members of one
association. This association gave us its membership
list, which contained 224 names.
Questionnaire survey
We drew a sample at random. To reach the number of
interviews envisaged we had to draw 142 names. The
people selected had to be currently working in the care
of mentally handicapped people. Twenty six failed to
satisfy this criterion; 15 others were untraceable or
unable to participate because they had been ill for a long
time. Twelve of the 101 people selected who satisfied the
selection criterion and could be traced refused to
participate. The 89 doctors reported all deaths of
patients for whom they were the attending physician
that occurred from 1 March 1991 to 1 March 1996.
When less than five years were covered the doctor
indicated the actual period. Deaths in hospital and
deaths occurring while the respondent was working as a
locum were excluded. Eighty nine doctors completed a
questionnaire, which comprised six questions for each
case, including whether an end of life decision had been
taken. Doctors were recommended to use the patients’
files while filling in the questionnaire. To estimate annual
absolute numbers, we used a weight of 1.79 on the basis
of the proportion of doctors represented in the sample.
Interviews
Sixty eight doctors mentioned at least one case in
which they had taken an end of life decision, and they
were invited to be interviewed about the most recent
such death. One refused. Finally, 67 interviews took
place between March and June 1996. The interviews
were conducted by eight trained interviewers. All of
them had experience as a doctor in caring for mentally
handicapped people. The interviews lasted between
one hour and two and a half hours.
The decisions we studied were withholding and
withdrawing life prolonging treatments (non›
treatment decisions), relieving pain and symptoms with
opiates in dosages that may have shortened life, and
ending life by giving lethal drugs (euthanasia by lethal
injection). The interview schedules contained many
questions identical with those in the Remmelink
questionnaire.1 2 Because most mentally handicapped
patients are incompetent, a refinement was made
about the patient’s request. We asked in detail about
patients’ other actions such as non›autonomous
requests or non›verbal communication. Examples of
non›autonomous requests were patients saying that
they wanted to go to heaven or that they wanted to be
left alone. Non›verbal communication included actions
of the patient that were interpreted by the doctor or
others as a wish to die or stop treatment—for example,
constantly removing a feeding tube or resisting all
medical treatment.
Mental handicap and diseases were classed accord›
ing to ICD›10 (international classification of diseases,
10th revision).
Results
Reported deaths
No patient had died in the previous five years for 10 of
the 89 respondents, while the remaining 79 doctors
reported 859 deaths in an average period of 4.7 years.
Of these 79 doctors, 11 had not taken an end of life
decision and 68 had taken such a decision in 350 out of
859 cases (41%); 254 were decisions to withhold or
withdraw treatment, 92 were to relieve pain and
symptoms with opiates, and four were to end life with a
lethal drug (table 1).
The number of reported deaths differed consider›
ably from year to year. However, the proportions of the
various types of decisions were similar. We estimated
absolute numbers for 1995 on the basis of 222
Table 1 Incidence of types of end of life decision in mentally
handicapped people in institutions. Values are numbers
(percentages) of deaths
All deaths
(n=859)
Deaths in 1995
(n=222)
End of life decision:
Non›treatment 254 (30) 75 (34)
Pain and symptom relief 92 (11) 22 (10)
Euthanasia* 4 (0.5) 0
No end of life decision 506 (59) 124 (56)
Unknown 3 (0.3) 1 (0)
*By lethal injection.
Table 2 Characteristics of patients in most recent cases of deaths in which end of life
decision was taken. Values are numbers (percentages) of deaths
Type of end of life decision
Non›treatment
(n=44)
Pain and symptom
relief (n=20) All (n=67)*
Sex:
Male 21 (48) 10 (50) 33 (49)
Female 23 (52) 10 (50) 34 (51)
Age (years):
0›49 15 (34) 8 (40) 25 (37)
50›64 16 (36) 10 (50) 26 (39)
65›79 10 (23) 1 (5) 12 (18)
>80 3 (7) 0 3 (5)
Unknown 0 1 (5) 1 (1)
Degree of mental handicap:
Mild 3 (7) 1 (5) 4 (6)
Moderate 17 (39) 10 (50) 29 (43)
Severe 11 (25) 4 (20) 15 (22)
Profound 12 (27) 3 (15) 16 (24)
Unknown 1 (2) 2 (10) 3 (5)
Diagnosis†:
Cancer 8 (18) 8 (40) 16 (24)
Diseases of nervous system‡ 30 (68) 14 (70) 47 (70)
Diseases of respiratory system 17 (39) 11 (55) 31 (46)
Diseases of digestive system¶ 19 (43) 5 (25) 26 (39)
Other diseases 27 (61) 3 (15) 34 (51)
Patient’s competency:
Incompetent 40 (91) 20 (100) 63 (94)
Competent 4 (9) 0 4 (6)
*Including three cases of euthanasia by lethal injection.
†More than one reply could be given to this question.
‡Including stroke and dementia.
¶Including endocrine, nutritional, and metabolic diseases.
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reported deaths and the distribution of decisions to
end life for that year. This resulted in an estimated total
of 397 deaths. For these deaths we estimated that there
would be 135 decisions to withhold treatment, 40
decisions to relieve pain and symptoms with opiates,
and 222 deaths with no end of life decision. Although
we found no decisions to end a patient’s life with a
lethal injection in 1995, we assumed that one or two of
these decisions would have occurred in that year on the
basis of the four cases in the whole sample.
Interviews
Sixty seven doctors described the most recent death in
which they had taken an end of life decision (tables 2, 3
and 4). Most doctors were trained as general
practitioners (49) and were experienced, having spent
an average of 13 years working in this specialty. Thirty
six doctors said that they considered themselves to be
part of a religious community. Most of the people who
had died were under 65 years old, and almost all were
considered by the doctor to be incompetent (table 2).
They lived in 51 institutions with an average number of
427 residents. Many had diseases of the nervous and
digestive systems. Two patients explicitly asked to die.
Twenty three doctors said that they had noticed
non›autonomous requests and relevant non›verbal
communication (table 3).
The most common reason for taking the decision
was the pain or suffering of the patient (19 doctors;
table 3). In 46 cases the doctor discussed the decision
with a colleague. Nurses were almost always consulted
(60). Relatives or representatives were less often
brought in (50), and consultation with the patient was
reported in two cases (table 4).
Three cases of euthanasia were reported. These are
included in the third column of tables 2, 3, and 4. The
patients in these cases had severe illnesses, including
severe heart problems (two patients), tetraplegia, severe
epilepsy, and recurrent pneumonia (two patients). In
two cases the suffering of the patient had increased
substantially before the decision was taken, and the
doctors saw no more options to alleviate this suffering.
In the other case the doctor mentioned that the
terminal phase had started. The doctors estimated that
the lives of the patients were shortened by one week at
most in all cases. All of them were incompetent and did
not express their wishes about the decision. One
patient, however, had refused hospital care a year
before the decision, when he could still communicate.
The doctors consulted a colleague or the nursing staff,
or both, in all cases, and two doctors discussed the
decision with the patient’s relative or representative.
Deaths were reported as natural in all cases.
Discussion
The study included more than half of all doctors caring
for mentally handicapped people in institutions, and
the number of refusals was low. The doctors were asked
to report only the deaths of patients for whom they
were the attending physician. We believe that the
questions were answered reliably because most doctors
had the case files with them at interview. The distri›
bution of the types of end of life decisions overall and
in 1995 is similar. Our estimated total number for 1995
is close to the 412 deaths reported by the Dutch associ›
ation for care of the mentally handicapped for 1994
(which is currently the most recent number available).6
A limitation of our study is the focus on the last end of
life decision. This ignores the fact that such decisions
are the result of a process rather than instantaneous.
Our results show that end of life decisions are an
important aspect of care for mentally handicapped
people. We found no comparable studies in this
specialty. A recent study on medical practices at the
end of life found that an end of life decision had been
taken in 43% of deaths,3 a proportion that is nearly
identical with the 41% that we found overall. This simi›
larity might suggest that the debate in the care of
mentally handicapped people is similar to that in other
specialties. However, distinctive features of this specialty
Table 3 Reasons why end of life decision was taken in most recent deaths. Values are
numbers (percentages) of deaths
Types of end of life decision
Non›treatment
(n=44)
Pain and
symptom
relief (n=20) All (n=67)*
Request by patient:
Explicit 2 (5) 0 2 (3)
Non›autonomous 6 (14) 1 (5) 7 (10)
Non›verbal communication 12 (27) 4 (20) 16 (24)
None 24 (55) 15 (75) 42 (63)
Most important reason for decision:
No chance of improvement 9 (21) 2 (10) 11 (16)
Pain and suffering of the patient 7 (16) 10 (50) 19 (28)
Life would be needlessly prolonged 8 (18) 3 (15) 12 (18)
All medical treatment had become futile 7 (16) 2 (10) 9 (13)
Wish of patient 4 (9) 0 4 (6)
Wish of relative or representative 2 (5) 0 2 (3)
Low quality of life 5 (11) 1 (5) 6 (9)
Undignified dying 1 (2) 2 (10) 3 (5)
Other 1 (2) 0 1 (1)
Intention of doctor:
Had taken into account probability that death would be
hastened
33 (75) 20 (100) 53 (79)
Partly to hasten death 9 (21) 0 9 (13)
To hasten death 1 (2) 0 4 (6)
Unknown 1 (2) 0 1 (1)
Estimated amount of life shortening:
None 11 (25) 9 (45) 20 (30)
<24 Hours 1 (2) 4 (20) 5 (7)
1 Week at most 7 (16) 4 (20) 14 (21)
1›4 Weeks 13 (29) 0 13 (20)
1›6 Months 6 (14) 2 (10) 8 (12)
>6 Months 4 (9) 1 (5) 5 (7)
Unknown 2 (5) 0 2 (3)
*Including three cases of euthanasia by lethal injection.
Table 4 Process of decision making in most recent deaths in which end of life
decision was taken. Values are numbers (percentages) of deaths
Type of end of life decision
Non›treatment
(n=44)
Pain and symptom
relief (n=20) All (n=67)*
Doctor discussed decision with†:
Patient 2 (5) 0 2 (3)
Colleague(s) 28 (64) 16 (80) 46 (69)
Nursing staff 39 (89) 19 (95) 60 (90)
Patient’s relative or representative 35 (80) 13 (65) 50 (75)
Educationalist 18 (41) 2 (10) 21 (31)
No one 3 (7) 0 3 (5)
Consensus about decision with all discussants 40 (91) 20 (100) 63 (94)
*Including three cases of euthanasia by lethal injection.
†More than one reply could be given to this question.
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make separate discussion necessary. Professionals caring
for mentally handicapped people have long term
relationships with patients. Nurses’ observations of the
communication and needs of patients are important in
decision making. Not only nurses but also representa›
tives of the patient should be included in decision mak›
ing. Until now, only autonomous requests by competent
patients were considered important in end of life
decisions. This is probably because the idea of autonomy
is paramount. Moreover, when a decision has far reach›
ing consequences, as in end of life decisions, more strin›
gent requirements for competency should be applied.7 8
We think that regardless of competency, all expressions
that might indicate the patient’s wishes are important.
Relevant expressions that are non›autonomous in the
strict sense were noticed in 34% of our cases. Therefore,
the role of communication with incompetent patients
should be reconsidered.
The amount of time that life was shortened because
of non›treatment in our study seems to be lower than
that found in nursing homes in 1991 (life was shortened
by 1›6 months in 32% of cases1 v 14% (6/44) of cases in
our study (table 3)). This suggests that end of life
decisions are taken later in the course of illness in men›
tally handicapped people. An explanation could be that
patients who are mentally handicapped are cared for in
institutions, and the handicaps are usually not progres›
sive lethal diseases. Also, doctors could be more reserved
in deciding to hasten death in such patients.
Because of the distinctive features of care for
mentally handicapped patients we believe that the
difference in openness of debate between this and other
specialties should be removed. A public discussion that
resonates more fully with the predicaments of caring for
mentally handicapped people could greatly contribute
to the quality of care at the end of life of these patients.
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Any questions
Ultraviolet light for psoriasis
Where does the balance of advantage lie in the effect of ultraviolet light
for people with psoriasis?
Approximately 80% of people with psoriasis will observe that
their psoriatic plaques are improved by exposure to natural
sunlight, 10% notice no difference, and 10% report deterioration.
This observation has led to the widespread use of artificial
ultraviolet radiation as one method of treating psoriasis either
singly or in combination. Broad band ultraviolet B (290›320 nm)
has been widely used for many years either as monotherapy or to
augment the effects of topical agents such as topical tar and
dithranol. Several studies of large populations of patients with
psoriasis have failed to find an increased incidence of any type of
cutaneous or systemic malignancy in patients with psoriasis
treated in this way compared with local controls.1 2
A new addition to treatment with ultraviolet B is the narrow
band TLO1 lamp emitting radiation at 312 nm. This wavelength
clears psoriatic plaques more rapidly than older broad band
ultraviolet B sources but not enough data are available to report
on the ratio of risk and benefit of this approach. Ultraviolet A or
longwave artificial ultraviolet sources (320›360 nm) may benefit
some patients with psoriasis who use sunbeds which are usually
equipped with tubes emitting this wavelength, but for greater
benefit a systemic photosensitising agent, a psoralen (PUVA), is
usually added. While PUVA is effective in clearing stubborn
psoriasis it is teratogenic and full contraceptive precautions must
be taken by young women. There is now also evidence that high
total cumulative doses of ultraviolet A given with a psoralen
photosensitiser lead to an increased incidence of squamous cell
carcinoma, but not of other malignancies. The risk is greater in
those who have used other carcinogenic agents as part of their
treatment, such as methotrexate, but is still seen in patients who
have used only PUVA.3
Traditional broad band ultraviolet B sources are safe and
non›carcinogenic if used in controlled conditions for intermittent
courses (commonly three exposures a week for six weeks). There
are no data on the new narrow band source or on ultraviolet A
used alone.
Rona M Mackie is professor of dermatology in Glasgow
1 Stern RS, Scott OJ, Fears TR. Psoriasis and susceptibility to non melanoma skin
cancer. J Am Acad Dermatol 1985;12:67›73.
2 Thune P, Flindt H, Mork C, Sterfelt F, Tigen K. Risk of skin cancer following
UVB phototherapy for psoriasis. In: Passchier WF, Bosnjakovic BFM, eds.
Human exposure to ultraviolet radiation risks and regulations. Amsterdam: Elsevier,
1987:53›7.
3 Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis.
Cancer 1994;73:2759›64.
Key messages
x Little is known about doctors’ decisions at the end of life that might
hasten death in the care of mentally handicapped patients
x This study shows that these end of life decisions are an important
aspect of care of mentally handicapped people in institutions,
occurring in around 40% of deaths
x As is the case in other specialties, a public debate about such
decisions could greatly contribute to the quality of care for mentally
handicapped patients
x The role of communication with patients should be reconsidered to
draw attention to the expressions of incompetent patients
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Who should decide? Qualitative analysis of panel data
from public, patients, healthcare professionals, and
insurers on priorities in health care
Karien Stronks, Anne›Margreet Strijbis, Johannes F Wendte, Louise J Gunning›Schepers
Abstract
Objective: To explore the arguments underlying the
choices of patients, the public, general practitioners,
specialists, and health insurers regarding priorities in
health care.
Design: A qualitative analysis of data gathered in a
series of panels. Members were asked to economise
on the publicly funded healthcare budget, exemplified
by 10 services.
Results: From a medical point of view, both panels of
healthcare professionals thought most services were
necessary. The general practitioners tried to achieve
the budget cuts by limiting access to services to those
most in need of them or those who cannot afford to
pay for them. The specialists emphasised the
possibilities of reducing costs by increasing the
efficiency within services and preventing
inappropriate utilisation. The patients mainly
economised by limiting universal access to preventive
and acute services. The “public” panels excluded
services that are relatively inexpensive for individual
patients. Moreover, they emphasised the individual’s
own responsibility for health behaviour and the costs
of health care, resulting in the choice for copayments.
The health insurers emphasised the importance of
including services that relate to a risk only, as well as
feasibility aspects.
Conclusions: There were substantial differences in
the way the different groups approached the issue of
what should be included in the basic package.
Healthcare professionals seem to be most aware of
the importance of maintaining equal access for
everyone in need of health care.
Introduction
As the costs of health care continue to increase and will
do so even more as our populations age the question
of what services a society can afford to offer to its
citizens continues to occasion debate. Recently readers
of the BMJ were confronted with a discussion of the
Swedish report on prioritising health care1 and on
Dworkin’s thought experiment on creative rationing.2
Central to this debate of course is the notion that there
are choices to be made. Previous studies have shown
that among the parties involved (public, professionals,
patients), no consensus exists for these choices.3›5 This
raises the question of whether the arguments used to
defend the different choices are consistent.
To develop some understanding about the
arguments underlying the opinions of different parties
we carried out a study with panels of five parties that
might be concerned in prioritising: the public and
patients, health insurers, and two groups of healthcare
professionals—general practitioners and medical
specialists. We report on their preferences but focus on
the criteria developed to select services to be included
in a basic package as well as the arguments used in
specific instances.
Subjects and methods
The study took place in the Netherlands. In the
Netherlands the (public) debate on prioritising health
care started almost 10 years ago. Several reports on this
issue have been published since then, the best known
of which is the report of the Dunning committee,
named after its chairman Professor Dunning.6 The
public debate has been stimulated by the
government—for example, by means of a campaign
aimed at making people aware of the necessity of
making choices.
In this study, six panels (box), consisting of about
nine people each, were asked to play the part of a
parliamentary committee with the decision to select
services that would continue to be funded from a
severely cut health budget. The list consisted of 10
different services, selected to represent different
aspects of physical health care (table 1). The decisions
to be made were restricted to those who receive public
insurance, which currently covers about two thirds of
the Dutch population.
The panels were given two sources of background
information: the selection criteria as proposed in the
Dunning report, Choices in Health Care: Necessary Care,
Effectiveness, Efficiency, Too Expensive for the Indi›
vidual (the criteria are summarised in the box on the
next page)6; and a file on each of the services under
consideration, containing information on its nature,
the number of people affected (now and in the future),
costs, and current restrictions. This information is sum›
marised in table 1. In addition, they received a few
papers stating the views of supporters and opponents
of public funding.
The panels were asked to economise nearly one
third of the total budget. They had to decide whether a
The panels
Patients:
People representing national patient groups
The public:
University students
Civil servants not working on health
(None of the members of these panels suffered from
a chronic illness or handicap)
Healthcare professionals:
General practitioners, in the last stage of their
training
Specialists in an academic hospital
Health insurers:
Employees working in a health insurance company
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certain service should be included in the basic package
(that is, provided with public funds) or removed from
the package, totally or partially. More importantly, they
had to give arguments for each choice. They were
given five hours to complete their task. One panel
member led the discussion. The discussions were
observed by one of the researchers and a facilitator
structured proceeding as necessary. To check the
unanimity of the outcomes of the discussion the panel
members were asked to fill out a questionnaire
afterwards concerning their private opinions. All
discussions were tape recorded and transcribed
verbatim.
The panels were not chosen to be a representative
sample of the population but were selected on
purpose. They represented five distinct parties in
health policy. The individual members of the panels
were selected by someone who was familiar with one of
the selected parties. The main selection criteria were:
interest in the subject, willingness to spend a full day on
the experiment, and availability. The “patient” panel
was the only one in which the members were also
formal representatives as they were all active officers of
national patient associations. There were two “public”
panels, one of which consisted mostly of university
students, who were thus on average younger than the
other panel members. Moreover, all participants were
well educated, which made it possible for them to
assess the information given even though they were
not familiar with it.
Results
All panels fulfilled their task, although with great diffi›
culty. It was obvious that most services could not be
easily excluded from coverage in a basic package and
that the budget cuts to be achieved were high. Table 2
summarises the choices made by each panel.
General practitioners
The general practitioners especially found themselves
in a dilemma as they could not really envision any of
the services being reduced without affecting patients in
real need of them. They therefore tried to achieve cost
reductions by limiting access to services, either to those
most in need of them or to those who cannot afford to
pay for them. For example, they discussed restricting
travel allowances to low income groups and decided to
pay for in vitro fertilisation only when a woman has no
or only one child. In addition, they decided to restrict
the universal accessibility of home care to nursing care
only, but the answers to the questionnaire they filled in
afterwards showed that most of the panel members felt
very uncomfortable about this decision. It is remark›
able that “responsibility of the individual” was not used
by this panel as an argument for exclusion of services.
Table 1 Services included in list and summary of the information given to panel members
Service Summary of background information given*
Costs (in million
Dutch guilders)† No of people affected
Home care Nature of care (mostly household support, care was only small part)
Age distribution of clients (mostly elderly people)
Copayments
Waiting lists
1740 About 7.5% of households
Circumcision for men Reasons for circumcision (about 60% of cost for religious reasons, rest of
costs: medical)
Providers: general practitioner, hospital (former much cheaper), and
traditional doctors
10 About 9000 circumcisions a
year
Homes for the elderly Copayments (costs of living paid by inhabitants themselves)
Future demographic developments
3185 About 6% of population
>65 years
Homoeopathic medicines Effectivity (effectiveness not proved yet)
Comparison with total costs of medicines (only 1% of total costs)
40 Many (exact number
unknown)
Screening for breast cancer Epidemiological data (incidence, etc)
Scientific basis of current programme (cost effectiveness study; number of
life years gained)
45 Women aged 50›70 years
(around 400 000)
Lung transplantation Characterisation of patients in need of transplantation
Waiting lists (limited number of transplant lungs)
Cost per transplantation, follow up included (about 300 000 Dutch guilders)
6 About 20 transplantations a
year
Travel allowances Nature of service (allowance of costs made in order to travel to healthcare
services)
Copayments
Future developments (higher costs because of demographic developments,
etc)
172 12% Of insured population
Oral contraceptives Nature of service (effective, risks almost nil)
Price for individual (maximum 100 guilders year)
145 About 35% of women aged
16›50 years
In vitro fertilisation Effectivity (similar to “natural” pregnancies but more complications)
Restrictions (maximum of 3 treatments publicly funded)
Costs per treatment
15 About 5500 treatments a year
Treatment of sport injuries Character of treatments (which sorts)
Nature of costs: costs of medical care
280 2.7 Million accidents a year
*Selective information only; information panels received was more extensive.
†Refers to publicly funded costs (in 1993), copayments excluded (around 3 Dutch guilders=£1($1.6)).
Dunning criteria
Publicly funded services should meet the following
criteria:
• Necessary care—care which is neceassary to
maintain or to restore health, defined as the ability to
function normally in the community
• Effectiveness—this has to be proved and
documented
• Efficiency—efficient delivery, based on the results of
cost effectiveness studies
• Individual responsibility—too expensive for the
individual
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This underlies the unanimous choice to include
treatment of sport injuries in the benefit package.
Specialists
The medical specialists also thought that most of the
services were necessary. Their criteria for inclusion
were the most explicit: prevention or curing of a
disease or caring for sick people. In their eyes infertility
was a disease thus in vitro fertilisation was included in
the basic package. Using that same argument, however,
they went on to exclude oral contraceptives. A second
argument used in that discussion emphasised that
most of the cuts proposed would affect old people. The
panel thought that excluding oral contraceptives was
one way to spread the effect more equitably over age
groups. They emphasised possible economies from
increased efficiency within the existing services, such as
home care and prevention of inappropriate use of
travel allowances. Compared with the other panels, the
specialist were more concerned about prevention and
hence included breast cancer screening.
Patients
The patients made a clear distinction between those
suffering from a long term or chronic illness and those
with an acute disease or healthy people. They thought
that especially health services for the former should be
publicly funded as chronically ill people have no other
option but to rely on health care. They therefore firmly
rejected cutting costs of long term home care and
travel allowances. On the other hand, they (partly)
excluded preventive services as well as severely cut
acute care (including short term home care after
hospital discharge) and health care needs related to
individual behaviour (such as treatment of sport
injuries).
Public
Both panels representing the public looked very care›
fully at the argument of financial resources of the indi›
vidual and individual responsibility for health. Those
services that were relatively inexpensive or allowed
alternative solutions for the individual were (partly)
excluded. These included travel allowance, oral contra›
ceptives, and in vitro fertilisation. These choices reflect
a high value placed on the principle of individual
responsibility, which was confirmed by the answers
given in the questionnaire. They proposed copayments
for health care in the case of sports injuries and breast
cancer screening, a decision consistent with their
earlier arguments.
Health insurers
The panel of health insurers introduced two criteria
specific to their occupational background. In the first
place they separated health risks (for which one can be
insured) and inevitable healthcare needs that will even›
tually be experienced by most of us (home care and
homes for elderly people). They thought that the latter
should be provided through taxation rather than
through insurance. They also emphasised the feasi›
bility of implementation of the measures proposed. For
that reason they argued against excluding sports
injuries or selecting those in real need for reimburse›
ment of travel allowances and in favour of the total
exclusion of oral contraceptives.
All panels
Despite these clearly distinct approaches to the
question of priorities, there were also some similarities.
All panels argued that homeopathic medicines should
be excluded from public funding as their effectiveness
has not been proved. They all decided to cut down the
costs of the homes for elderly people, the underlying
rationale being the wish to deliver services more
efficiently. In addition, the panels seem to agree on the
value of lifesaving services, as exemplified by lung
transplantation. Yet all groups questioned the cost›
benefit ratio of this service, which reflects the high
value attached to efficiency.
Discussion
The panels were able to reach a consensus, although it
was obvious that many of the concepts used and much
Table 2 Choices made by each panel as to whether service should be publicly funded
Service General practitioners Specialists Patients
Public
Health insurersStudents Civil servants
Home care Partly: medical care only Partly: higher copayments +
cost reduction by increased
efficiency
Partly: long term care only Partly: medical care only Yes Partly: short term
care only
Circumcision for men Partly: medical
indication only
Partly: copayments in case of
religious reason
Partly: copayments in case
of religious reason
No Partly: medical
indication only
No
Homes for the elderly Yes + cost reduction by
limiting access to people
most in need
Yes + cost reduction by
limiting access to people most
in need
Yes+ cost reduction by
limiting access to people
most in need
Yes + cost reduction by
limiting access to people
most in need
Partly: medical care
only
No
Homoeopathic medicines No No No No No No
Screening for breast
cancer
Yes Yes Partly: copayments Yes Partly: copayments Yes
Lung transplantation Yes Yes Yes Yes Yes Yes
Travel allowances Partly: those most in
need only + copayments
Yes + cost reduction by
preventing inappropriate
utilisation
Yes + cost reduction by
preventing inappropriate
utilisation
No Partly: copayments No
Oral contraceptives Partly: medical
indication only
No Partly: medical indication
only
No Partly: medical
indication only
No
In vitro fertilisation Partly: access restricted
+ copayments
Yes No No No No
Treatment of sport
injuries
Yes + reducing costs by
increased efficiency
Yes No Partly: copayments No Yes
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of the material offered were alien to many of the panel
members. It is therefore unlikely that an exercise like
this could be easily used to elicit opinions of the
general public. Additional evidence to support this
view is provided by a recent experiment on citizens’
juries among the general public.7 That experiment
showed that if the general public is to be involved in
decisions on prioritising in health care they need much
more time and information than the five hours and the
written information that the participants in our study
were given.
Given the fact that the panel members were
relatively young and highly educated, they were far
from random samples. Therefore the panels should
not be considered as representing the whole
population of patients, general practitioners, etc. It
could be questioned whether this threatens the validity
of our results. In general demographic characteristics
do not seem to be systematically related to the
decisions people make in prioritising processes.8 An
exception should probably be made for age as a recent
study showed that people seem to favour services for
their own age group.5 If this is true, the panels probably
would have been more reluctant with respect to cutting
costs for home care and homes for the elderly if more
elderly people had been included. On the other hand,
a specific check on the age distribution of the proposed
cuts was discussed explicitly by at least one of the
panels. Moreover, our aim was to obtain more insight
into the arguments underlying the choices of different
actors in the decision making process, rather than into
the outcome of the prioritisation process. We do not
consider it likely that the arguments strongly differ by
age or other characteristics.
In view of the limited share of resources that can be
devoted to health care, all panels chose to exclude
ineffective services from public funding and tried to
deliver services more efficiently. Hence the idea of
effectiveness and efficiency as necessary conditions for
the general accessibility of our future healthcare
system seems widely shared. This was confirmed by the
data obtained by the questionnaire. In addition, all
groups seemed to agree on the value of lifesaving tech›
nologies. The discrepancy with the results of other
studies suggesting that the public and professionals
disagree in this respect3 9 might be explained by the
fact that we chose lung transplantation as an example
of high technology, a service which mostly benefits
young people. Moreover, the costs of this service
represented only a small proportion of the total
budget.
Observed differences
Besides these similarities we observed substantial
differences in the arguments of the groups considered.
Patients and health insurers in particular explicitly
introduced self interest as a basis for prioritising. The
patients, all suffering from a chronic illness, considered
care services to be the most important, which
corresponds with the results of another study
regarding primary healthcare services.4 The choices of
the health insurers were guided mainly by their
concern for the practical feasibility of the chosen
strategy. We found little evidence to suggest that the
public or healthcare professionals were guided by
personal needs or self interest, which is consistent, as
far as the public is concerned, with the results of a pre›
vious study.10
Partly because of differences in the approach to the
population’s best interest, but probably also because of
differences in first hand experience with the people
using the different services discussed, the main
difference between the panels seems to be the extent to
which they took the principle of equal access into con›
sideration. This finding seems to be in accordance with
that of a previous studies.3 11 Members of the public
panel in particular frequently emphasised the
importance of individual responsibility. In accordance
with this principle, copayments were proposed without
paying much attention to whether this might affect the
accessibility of health care for low income groups.
Although the outcome here may have been biased by
their relatively high level of educational and income,
the results of a survey among a random sample of the
public3 also showed that priorities set by the general
public might be contrary to the principle of equity and
equal access. In addition, while focusing on a
conception of health care in terms of care for the
chronically ill, the strategy of the patients might
threaten the accessibility for those with an acute illness
or healthy people. In contrast, the healthcare
professionals, and in particular the general practi›
tioners, explicitly took into account the consequences
of their decision for the equal accessibility of services.
In addition, the specialists discussed the distribution of
the proposed economies across age groups.
Finally, the healthcare professionals were the most
pessimistic about the possibilities of cutting down
public expense on health care. The strategy of not
offering those services under public funding was
hardly an acceptable option to them, whereas the
possibilities for other strategies, such as restricting
access to specific groups, was limited by the high value
attached to the principle of equal access. A cynic might
argue that doctors would be expected to be most
reluctant to cut healthcare costs out of self interest, but
the arguments used and the tone of the discussion
suggest otherwise. The difficulties encountered by the
healthcare professionals in the decision making seem
Key messages
x Interest in the opinions of different parties
concerned with the process of prioritisation of
health services is high
x This study aimed at understanding the
arguments underlying the opinions of the
public, patients, healthcare professionals, and
insurers
x There seem to be substantial differences in the
way the different parties approach the issue of
what services should be collectively funded
x The main difference seems to be the extent to
which the parties took the principle of equal
access into consideration
x Including all the different parties in the decision
making process will therefore not necessarily
lead to more equitable or broadly supported
outcomes
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to reflect a more realistic picture of current practice in
health care, as well as a greater awareness of the
importance of maintaining equal access.
From our results it is not clear that including all the
different actors in the decision making process of
prioritisation of health services will lead to more
equitable or broadly supported outcomes or to better
health for the population. It is quite remarkable that it
is the medical profession that seemed most concerned
about the common good and the distribution of
services. The panels representing the public, patients,
and insurers had much more trouble weighting the
interests of all those concerned. As a result, their
decisions might threaten the universal accessibility of
core services. As this principle is highly valued in west›
ern societies this may be unacceptable for at least
professionals, as our results show, but also for policy
makers. The arguments put forward by the different
groups, however, are well worth considering because
they clearly reflect the different perspectives of those
affected by prioritisation. We think that they all deserve
to be carefully considered by the (democratically
elected) bodies that decide on resource allocation in
most of our healthcare systems.
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Genetic linkage of mild malaria to the major
histocompatibility complex in Gambian children: study of
affected sibling pairs
Annette Jepson, Fatoumatta Sisay›Joof, Winston Banya, Musa Hassan›King, Angela Frodsham,
Stephen Bennett, Adrian V S Hill, Hilton Whittle
Case›control studies have shown that genes for the
major histocompatibility complex influence the
presentation and outcome of severe Plasmodium
falciparum disease (cerebral malaria or severe
anaemia).1 2 To assess the role of these genes in mild
disease, we conducted a genetic analysis of sibling pairs
concordant for this phenotype. The affected sib›pair
method compares the observed and expected distri›
bution of parental alleles at marker loci inherited iden›
tical by descent (ibd). At any locus, a pair of siblings
may share 0, 1, or 2 alleles in the ratio 25%:50%:25%,
by random segregation. If a locus is genetically linked
to disease, affected siblings will share a higher number
of alleles identical by descent at that locus than
expected.
Subjects, methods, and results
We recruited 217 dizygous pairs of Gambian twins
(mean age 5.3 years).3 Twins living together are impor›
tant for such a study, for they are of the same age and
share a common environment. They were monitored
weekly during the 1991 rainy season for development
of fever and P falciparum infection. Clinical malaria was
defined as fever (axillary temperature >37.5+C) plus
P falciparum asexual parasitaemia >5000/ìl. Surveil›
lance continued through the next two rainy seasons,
producing a total of 40 pairs of twins who were
concordant for clinical malaria; none had severe
disease.
Major histocompatibility complex class II typing of
these children and their parents was by TaqI restriction
fragment length polymorphism analysis; the cDNA
probes used for hybridisation were specific for DRB
and for DQB. Additional typing was by fluorescence
labelled microsatellite markers that map to the
major histocompatibility complex region (d6s291,
d6s273, tnfa, d6s276). A maximum of four indi›
vidual alleles were labelled within each family. Analysis
was by gas (Genetic Analysis System, version 1.6; Alan
Young, Oxford) and the mapmaker/sibs program,
which uses a maximum likelihood method that takes
into account partially informative matings to infer
sharing of alleles identical by descent at the unknown
loci and thereby to compute, at each location, a
maximum lod score (log 10 of the likelihood of
estimated sharing divided by the likelihood of no
excess sharing).4
Four families had moved away from the study area
before the end of the study, and parents in four families
had inadequate samples; in nine families one parental
sample was not available, and in one family a parent
was homozygous at all of the loci tested. The 22 fully
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informative families were analysed by the gas program
(table 1).
The mapmaker/sibs program estimated the maxi›
mum likelihood values of the allele sharing pro›
portions for each marker for 32 families (the 22 above
plus the 10 families with incomplete data) to estimate
the maximum lod score, which was 2.77 (P < 0.001) at
the tnfa locus. For comparison, sharing of major histo›
compatibility complex alleles was not increased among
13 pairs of dizygous twins who were discordant for
clinical disease (only one member of each pair having
developed clinical malaria during the three year
observation period) (data not shown).
Comment
The significantly non›random sharing of alleles
indicates a large effect of the major histocompatibility
complex on risk of uncomplicated malaria. The
linkage approach may be a more powerful means of
assessing the overall influence of the complex in
infectious diseases, for previous studies of uncompli›
cated malaria have detected no association with
individual alleles.5 Three genes of the major histocom›
patibility complex are already known to affect the out›
come of malaria infections; others may remain to be
identified.
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tin Farrall for carrying out the analysis with the mapmaker/sibs
program.Funding: UNDP/World Bank/WHO Special Pro›
gramme for Research and Training in Tropical Diseases;
Wellcome Trust; Rockefeller Foundation; Medical Research
Council.Conflict of interest: None.
1 Hill AV, Allsopp CE, Kwiatkowski D, Anstey NM, Twumasi P, Rowe PA,
et al. Common West African HLA antigens are associated with protection
from severe malaria. Nature 1991;352:595›600.
2 McGuire W, Hill AV, Allsopp CE, Greenwood BM, Kwiatkowski D.
Variation in the TNF›á promoter region associated with susceptibility to
cerebral malaria. Nature 1994;371:508›10.
3 Jepson AP, Banya WA, Sisay›Joof F, Hassan›King M, Bennett S, Whittle
HC. Genetic regulation of fever in Plasmodium falciparum malaria in
Gambian twin children. J Infect Dis 1995;172:316›9.
4 Kruglyak L, Lander E. Complete multipoint sib pair analysis of qualitative
and quantitative traits. Am J Hum Genet 1995;57:439›54.
5 Bennett S, Allen SJ, Olerup O, Jackson DJ, Wheeler JG, Rowe PA, et al.
Human leucocyte antigen (HLA) and malaria morbidity in a Gambian
community. Trans R Soc Trop Med Hyg 1993;87:286›7.
(Accepted 12 December 1996)
A memorable patient
My only patient in general practice
I was a medical student, on my general practice
placement, and my medical knowledge was confined to
what a pharmacology intercalated BSc course and a
year’s clinical medicine had taught me. That morning,
the singlehanded general practitioner’s receptionist
said that he was ill and asked me to come back in an
hour’s time. I was naive enough for this to strike me as
ironic, and returned to find the receptionist and the
doctor’s non›medical wife looking worried. They asked
me to have a look at him. I was shocked to see him
heavily sedated, with pin point pupils. With a bit of
shaking I roused him and discovered that he had had
severe toothache the night before and had taken a
couple (or was it four?) Temgesic (buprenorphine)
tablets which a drug representative had left. Could he
have mixed them up in his mind with Distalgesic
(paracetamol)?
I was a bit concerned at his state, but equally unsure
what to do. My intercalated BSc swam vaguely into
consciousness. I strode to the teaching hospital which
was fortuitously nearby, found the dispensary, and
spoke with empty confidence to the pharmacist.
“I’m a medical student attached to Dr Jones’s practice
up the road. He’s got a patient who has taken an
overdose of opiates, and wants some intramuscular
naloxone. Can I have some quickly to take back please?”
The pharmacist was unimpressed.
“I don’t know about that. I’m not sure I have it to
hand, and, anyway, we can’t make up general
practitioners’ prescriptions.”
Before she could refuse again I said, “Look, if this
patient dies I should imagine you would be considered
wholly responsible. Naloxone is hardly the sort of
thing people abuse, is it?”
Perhaps the logic of the final remark impressed
her, or it might have been the distant possibility of
being in some way held responsible. She reluctantly
gave me two vials of naloxone, with strict
instructions to return with a prescription and further
explanation.
I ran back with the vials and found a syringe and
blue needle. Green seemed too big to be plausible, but
I had no idea what you were supposed to use. I had
never given any sort of injection, having previously
confined my instrumentation to venepuncture. Just
before I plunged the needle into his deltoid I asked,
“Are you a drug user? I should say so now if you are,
because I don’t know if this is going to give you
withdrawal symptoms serious enough to kill you.”
I thought he had shaken his head. I hoped so. I
hoped that intramuscular injections could not be fatal
in inexperienced hands and gave him the naloxone.
He came round. I had feared that he would be angry
but I was surprised to find that he seemed OK, even
grateful. Both vials were eventually needed.
I never went back to the dispensary. When I finished
the attachment I got a top grade and the comment
that my clinical pharmacology was exemplary.
James Barrett, senior registrar in psychiatry, London
We welcome filler articles of up to 600 words on topics
such as A memorable patient, A paper that changed my
practice, My most unfortunate mistake, or any other piece
conveying instruction, pathos, or humour. If possible
the article should be supplied on a disk.
Table 1 Distribution of shared alleles mapping to the major
histocompatibility complex by affected sibling pairs concordant
for malaria in 22 families with complete information (based on
the single most informative marker for each family)
No of pairs with
malaria
No of shared alleles
2 1 0
Observed 11.0 10.0 1.0
Expected 5.5 11.0 5.5
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